Clinical trials
Immune System Diseases clinical trials
Below are recruiting immune system diseases clinical trials, each written for real people, not researchers. We’re tracking 195 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07840196RecruitingPhase 1
Investigational drug NG004 for recent spinal cord injury
This trial tests a new drug called NG004 given by injection around the spinal cord. It aims to help people with recent incomplete spinal cord injuries recover function. The drug is given within the first month after injury and may be an option for those who meet the health criteria.
BayreuthAges 18–75 - NCT06778343Recruiting
Biomarkers study for inflammatory rheumatic diseases
This study is looking for people with ankylosing spondylitis, rheumatoid arthritis, or lupus to help find biomarkers that may make diagnosis easier. If you have one of these conditions and haven't tried biologic therapies, you may be able to join.
LisbonAges 18–65 - NCT07124078RecruitingPhase 2
Study of axatilimab for young people with chronic graft-versus-host disease
This study tests a new drug called axatilimab for children and teens with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The goal is to see if axatilimab works better than the usual care options. Participants will be randomly assigned to receive either axatilimab or one of several standard treatments.
Duarte, CaliforniaAges 2–17 - NCT06281327RecruitingPhase 2
Avatrombopag for children with ITP switching from eltrombopag
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
TianjinAges 6–18 - NCT00001184Recruiting
Studying the immune system in Crohn's and colitis
This study collects blood and tissue samples to better understand how the immune system behaves in people with inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. It aims to advance research rather than test a specific new treatment, and it also enrolls healthy volunteers for comparison.
Bethesda, MarylandAges 1 day–75 years - NCT07382739RecruitingPhase 2
Radiation and immunotherapy for advanced multiple myeloma
This trial tests whether combining radiation therapy with the drug elranatamab can help people with multiple myeloma that has come back or not responded to treatment, especially when the cancer has spread to soft tissues or bones outside the bone marrow. The goal is to see if this combination can make the immune system fight the cancer more effectively.
Houston, TexasAges Any age - NCT07273708Recruiting
Immune cell study in liver cancer patients on immunotherapy
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Pavia, LombardyAges 18–90 - NCT06523673RecruitingPhase 3
SBRT for lung cancer with limited new growth
This trial tests whether a precise type of radiation called SBRT can control lung cancer that has started to grow in only a few new spots while you are on standard treatments. It may help you delay changing to a different treatment.
Hangzhou, ZhejiangAges 18 years+ - NCT04854213Recruiting
Study checks radiation effects in colon cancer lung-limited spread
This trial studies how targeted radiation (SBRT) affects cancer biology and immune cells in people with colon cancer that has spread only to a small number of lung nodules. Your tumor tissue will be analyzed to see what changes after treatment.
Naples, NAPOLIAges 18–80 - NCT06898853Recruiting
Eye drops for dry eye: A 12-week study
This trial tests whether an anti-inflammatory eye drop (ciclosporin A) can help dry eyes by changing immune cells on the eye's surface. It lasts 12 weeks and may be an option for people with moderate to severe dry eye.
Sydney, New South WalesAges 18 years+ - NCT06660355RecruitingPhase 2
Comparing two medicines for chronic graft-versus-host disease
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
Miami, FloridaAges 18 years+ - NCT05736419RecruitingPhase 2
Immune-suppressing treatment before stem cell transplant for blood disorders
This Phase 2 study tests an immune-suppressing treatment for people with sickle cell disease or beta-thalassemia who are preparing for a stem cell transplant from a donor. It aims to help the transplant work better by changing the immune response.
Basking Ridge, New JerseyAges 2–50 - NCT03913962Recruiting
Exercise study for children with chronic or autoimmune conditions
This study looks at how physical activity affects muscle, metabolism (how your body uses energy), and body composition in children with certain chronic or autoimmune conditions. It may help doctors understand what types of exercise and monitoring are most beneficial and safe.
Clermont-FerrandAges 6–18 - NCT06581562RecruitingPhase 1
Testing rituximab plus AB-101 for autoimmune diseases
This trial tests a new treatment (AB-101) combined with rituximab for people with certain autoimmune diseases like rheumatoid arthritis, pemphigus vulgaris, vasculitis, or lupus. It is for those who have not had success with standard therapies.
Plantation, FloridaAges 18 years+ - NCT07750171Recruiting
How smoking affects healing around dental implants
This study looks at how smoking affects the body's immune response around dental implants that are healthy or have mild gum disease. It may help us understand why some implants develop problems and could lead to better care for smokers with implants.
Ankara, AnkaraAges 21–75 - NCT07696832Recruiting
Ivonescimab as first treatment for advanced lung cancer
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
Guangzhou, GuangdongAges 18 years+ - NCT07184450RecruitingPhase 1
CAR-T cell therapy for children with hard-to-treat rheumatic diseases
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
Hangzhou, ZhejiangAges 5 years+ - NCT00404560Recruiting
Blood tests to study infection risk and immune problems
This study looks at how the immune system works in people who have—or might have—an increased risk of infections. It also enrolls their healthy blood relatives so researchers can compare immune features; results may help doctors understand who is at higher risk and why.
Bethesda, MarylandAges 1 month–100 years - NCT07284641RecruitingPhase 2
Stem cell transplant for immune disorders
This trial tests a stem cell transplant to treat common variable immunodeficiency (CVID) and other immune problems. It aims to replace a faulty immune system with a healthy one from a donor.
Pittsburgh, PennsylvaniaAges 5–40 - NCT07362238RecruitingPhase 2
Daratumumab vs Rituximab for pediatric ITP
This study compares daratumumab to rituximab for children with primary immune thrombocytopenia (ITP) that hasn't improved with steroids. The goal is to find a better treatment to raise platelet counts and reduce bleeding risk.
TianjinAges 6–18 - NCT07297563RecruitingPhase 2
Anti-CD38 antibody vs rituximab for hard-to-treat ITP
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07063199RecruitingPhase 2
Anti-CD38 antibody for older adults with hard-to-treat ITP
This trial tests an investigational antibody (anti-CD38) for older adults with ITP that hasn't improved with standard treatments. The goal is to see if this antibody can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 60 years+ - NCT06838962RecruitingPhase 2
Study of anti-CD38 antibody for children with chronic ITP
This trial tests a new antibody treatment (anti-CD38) for children ages 6 to 18 who have had low platelets for at least 3 months and did not improve with steroids. The goal is to see if this treatment can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 6–18 - NCT07333313Recruiting
Study of oral medicine and probiotics for kidney disease in diabetes
This trial tests if an oral medication that absorbs toxins plus probiotics can reduce inflammation and slow kidney damage in people with diabetes-related kidney disease (DKD). It may help those with mild to severe kidney function loss.
Taipei, TaiwanAges 20 years+
Hear when a new Immune System Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune system diseases?
- Yes. Clin2 currently lists 195 recruiting immune system diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune system diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune system diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.